Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Core Insights - Eli Lilly aims to establish India as a global export hub for its pharmaceutical products, leveraging a $1 billion investment in contract manufacturing [1] - The company's weight-loss drug Mounjaro has seen sales double shortly after its launch in India, becoming the top-selling medicine by value in the country [1] - Lilly plans to introduce additional products in India, including the Alzheimer's drug donanemab and potential future obesity treatments, pending regulatory approvals [1] Company Strategy - Eli Lilly does not currently have its own manufacturing facility in India but intends to export drugs produced locally to global markets [1] - The company is focused on enhancing digital and social media campaigns to raise awareness about obesity and expand Mounjaro's reach in smaller cities [1] - Partnerships with local firms, such as Cipla and digital health platforms like Tata 1MG, Practo, and Apollo, are part of Lilly's strategy to widen distribution [1] Market Competition - In India, Eli Lilly competes with Novo Nordisk, which produces Wegovy, as the market for weight-loss drugs is expected to grow significantly [1] - Novo Nordisk has reduced the price of Wegovy by up to 37% to maintain market share, but Lilly believes Mounjaro's superior efficacy will keep it competitive [1] - The expiration of Novo's patent on semaglutide is anticipated to lead to the launch of cheaper generic versions of Wegovy by local firms [1]